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Glioblastoma multiforme (GBM) is a highly invasive brain tumor that develops florid microvascular proliferation and hemorrhage. However, mechanisms that favor invasion versus angiogenesis in this setting remain largely uncharacterized. Here we show that integrin β8 is an essential regulator of both GBM-induced angiogenesis and tumor cell invasiveness. Highly angiogenic and poorly invasive tumors expressed low levels of β8 integrin, whereas highly invasive tumors with limited neovascularization expressed high levels of β8 integrin.
Manipulating β8 integrin protein levels altered the angiogenic and invasive growth properties of GBMs, in part reflected by a diminished activation of latent transforming growth factor βs (TGFβs), which are extracellular matrix (ECM) protein ligands for β8 integrin. Taken together, these results establish a role for β8 integrin in differential control of angiogenesis versus tumor cell invasion in GBM. Our findings suggest that inhibiting β8 integrin or TGFβ signaling may diminish tumor cell invasiveness during malignant progression and following anti-vascular therapies.
Introduction:
Astrocytomas, which arise from presumptive astrocytes and/or neural progenitor cells of origin (1), afflict approximately 20,000 people within the United States each year (2) . They represent the most common type of primary brain tumor, and in their malignant stages they are one of the deadliest forms of cancer. Multiple chromosomal abnormalities and gene expression defects correlate with astrocytoma initiation and progression (3) . For example, low grade astrocytomas commonly display loss of p53, and as these tumors progress to more malignant stages they often show deletion of the Ink4/Arf tumor suppressors (4) . Grade IV astrocytomas, or GBMs, commonly display amplification of PDGF-B and/or EGF receptor expression, leading to hyperactivation of downstream signaling cascades often involving Ras (5) .
GBMs develop unique angiogenesis pathologies including microvascular hyperproliferation well as edema and hemorrhage owing to breakdown of the intratumoral blood-brain barrier (6) . GBM cells are also highly infiltrative, often dispersing to distal regions of the brain via white matter tracts and vascular basement membranes (7, 8) . GBM-induced angiogenesis and tumor cell invasiveness are tightly coupled pathologies. For example, antivascular therapies commonly enhance perivascular GBM cell invasiveness, leading to the development of secondary lesions that are resistant to second-line therapies (9, 10) .
GBM-induced angiogenesis and tumor cell invasion are influenced by a milieu of growth factors and extracellular matrix (ECM) cues within the brain microenvironment (6) . Most mammalian cells communicate with protein components in the ECM via a family of cell surface receptors known as integrins (11) . The five members of the αv integrin subfamily-αvβ1, αvβ3, αvβ5, αvβ6 and αvβ8-are expressed in neural and vascular cells of the brain and bind to RGD peptide motifs present in many shared ECM ligands (12) . In particular, genetic studies in mice have revealed that αvβ8 integrin is a central regulator of angiogenesis in the developing brain (13, 14) . Targeted ablation of αv or β8 integrin genes in embryonic neuroepithelial cells causes brain-specific vascular phenotypes, including endothelial cell hyperproliferation, the formation of vessels with glomeruloid-like tufts, and intracerebral hemorrhage (15, 16) . These pathologies are due to defective activation of latent TGFβs, which are ECM-bound protein ligands for αvβ8 integrin (17, 18) . In neurogenic regions of the adult mouse brain αvβ8 integrin is expressed in neural stem and progenitor cells where it governs proper neurogenesis (19) and neuroblast migration (20) .
αvβ8 integrin expression and functions are dysregulated in various brain pathologies.
For example, diminished expression of αvβ8 integrin and reduced TGFβ signaling are detected in brain arteriovenous malformations (21) . We have discovered that αvβ8 integrin-activated TGFβs suppress pathological angiogenesis in mosaic mouse models of astrocytoma (22) . Here, we have analyzed roles for αvβ8 integrin in angiogenesis and tumor cell invasiveness in human GBM. Using xenograft models as well as cell culture systems we demonstrate that β8 integrin differentially regulates these GBM pathologies, in part, via autocrine activation of TGFβ signaling pathways.
Materials and Methods:
GBM cell lines and human tumor samples: Approval for the use of human specimens was U87, LN18, LN229, SNB19, and U373 GBM cell lines were purchased from ATCC (Manassas, VA). Short tandem repeat analyses by ATCC have revealed that SNB19 and U373 are from the same patient. All cells were grown in DMEM/F12 (Mediatech) supplemented with 10% fetal bovine serum (Atlanta Biologics) and antibiotics. Normal human astrocytes were purchased from Lonza, Inc. Transformed human astrocytes (THAs) have been described elsewhere (23) .
β8 integrin protein was overexpressed in U87 cells using a pcDNA4.0 plasmid harboring a fulllength human β8 integrin cDNA fused at the C-terminus with a V5 epitope tag. After selection for 10 days in 300 μg/ml zeocin stable transfectants were pooled and analyzed.
Antibodies: The following antibodies were purchased from commercial sources: rat anti-mouse CD34 mAb (Genetex), rat anti-mouse CD31 (Pharmingen), rabbit anti-α-actin (Sigma) and mouse anti-human αv integrin mAb (BD Biosciences). FITC-conjugated phalloidin was purchased from Sigma. The anti-αv integrin and anti-β8 integrin rabbit polyclonal antibodies used for immunoblotting have been described elsewhere (24, 25) . Secondary antibodies were goat anti-rabbit, goat anti-chicken, goat anti-rat and goat anti-mouse, all conjugated to Alexa488 or Alexa594 (Molecular Probes). HRP-conjugated secondary antibodies used were sheep antimouse, goat anti-rabbit and donkey anti-chicken IgY (Jackson ImmunoResearch Labs). NIH ImageJ software was used for quantitation of intratumoral blood vessel densities based on anti-CD34 fluorescence intensity.
To generate the anti-β8 integrin antibody used for GBM immunohistochemistry a 43-kDa fragment of the β8 integrin extracellular domain (β8ex) was expressed in bacteria as a GST fusion protein using the pGEX-6P expression plasmid (GE Healthcare). The DNA primer sequences used to amplify the β8ex region are: 5'-TCAGTTGATTCAATAGAATACC-3' and 5'-CTGTGTATATGAATTTTAGCG-3'. GST-β8ex protein (~67 kDa) was found exclusively in detergent-insoluble inclusion bodies. GST-β8ex was solubilized in buffer containing 6M urea and sequentially dialyzed into urea-free buffer. Soluble recombinant protein was fractionated using glutathione-Agarose. The GST portion was cleaved using Precision Protease (GE Healthcare) to liberate the 43-kDa β8ex protein, which was used to immunize rabbits (Covance).
Immunohistochemistry and immunofluorescence: Formalin fixed paraffin embedded (FFPE) sections were deparaffinized in 2 changes of xylene and then dehydrated in 2 changes of 100% ethanol, 95% and 80% ethanol, and distilled water. For anti-αv integrin immunohistochemistry, slides were incubated 95-100°C with pH 9.0 antigen retrieval buffer (DAKO) for 40 minutes and then transferred to room temperature prior to immunostaining. Alternatively, deparaffinized sections were incubated in blocking solution and then primary anti-β8ex antibody was added.
Sections were rinsed three times with PBS, blocked with peroxidase solution, incubated with secondary antibodies conjugated to HRP, and then VIP or DAB chromagens were added to visualize immunoreactivity. For quantitation of blood vessel densities in tumors generated from U87 cells and THAs, digital images were selected from three intratumoral regions labeled with anti-CD34 antibodies. Three serial sections were analyzed from 3 different mice injected with the various cell types. Mean fluorescence intensity was calculated using NIH ImageJ software.
Two investigators, who were blinded to the identities of each sample, analyzed sections. PAI1-Luciferase assays: THAs were transiently transfected with a PAI1-Luciferase plasmid (27) . Alternatively, siRNA pools (Dharmacon) targeting human β8 integrin were transfected into LN229 GBM cells using manufacturer-supplied transfection reagents and protocols. 48
hours after transfection cells were either lysed to confirm integrin silencing by immunoblotting, or analyzed in the matrigel invasion system using 5 x 10 4 cells per transwell as detailed above. Results:
Analysis of β8 integrin protein expression patterns in human GBM cell lines in vitro and

GBMs in situ:
We used anti-β8 integrin and anti-αv integrin antibodies to screen normal human astrocytes (NHAs), transformed human astrocytes (THAs), and 7 different human GBM cell lines for levels of integrin protein expression. As shown in Figure 1A , all cell types expressed similar levels of αv integrin protein, whereas β8 integrin protein was expressed at varying levels in the different cell types. NHAs expressed robust levels of β8 integrin and oncogene-mediated transformation of these cells resulted in a significant reduction in integrin protein expression.
The human GBM cell lines U373, LNZ208, LN428, SNB19 and LN229 cells all expressed robust levels of β8 integrin protein. In contrast, U87 and LN18 cells expressed low or undetectable levels of β8 integrin protein ( Figure 1A ). Plasma membrane expression of αvβ8 integrin protein was confirmed using a membrane-impermeable reactive biotin derivative to label cells. Detergent-soluble lysates were then immunoprecipitated using anti-αv and anti-β8 integrin antibodies to reveal cell surface expression (Supplemental Figure 1 ).
We also compared integrin expression levels by immunoblotting lysates prepared from 7 different freshly resected GBM samples. All samples expressed similar levels of αv integrin protein, and 6 of the 7 samples expressed robust levels of β8 integrin protein with one sample expressing lower levels of β8 integrin ( Figure 1B ). Robust levels of αvβ8 integrin protein were also detected in lysates prepared from three freshly resected grade III anaplastic astrocytomas, two grade IV oligodendrogliomas, and one gliosarcoma (data not shown).
The anti-β8 integrin antibody used for immunoblotting ( Figures 1A, B) was not compatible for immunohistochemical labeling of formalin fixed paraffin embedded (FFPE) tumor sections. Therefore, we generated polyclonal antisera directed against the extracellular portion of human β8 integrin. The antiserum is highly specific for human β8 integrin protein and shows minimal cross-reactivity with mouse β8 integrin (Supplemental Figures 2 and 3) . FFPE samples corresponding to three of the 7 GBM samples analyzed in Figure 1B were analyzed by anti-αv and anti-β8 integrin immunohistochemistry. As shown in Figures 1C, a commercially available anti-αv mAb revealed integrin protein expression in intratumoral blood vessels as well as in GBM cells. The immunoreactivity was likely due to αvβ3 integrin, which is expressed in vascular endothelial cells of GBMs and other malignant neural tumors (28, 29) . We detected β8 integrin protein expression in most GBM cells ( Figure 1C) ; however, little if any β8 integrin protein was detected in the intratumoral vasculature. These data are consistent with a prior report showing β8 integrin mRNA and protein expression in human GBM cells but not blood vessels (30) .
These immunohistochemical results confirm our analyses of αv and β8 integrin protein expression in lysates prepared from normal human astrocytes, GBM cell lines, and GBMs ( Figures 1A, B) .
Exogenous expression of β8 integrin in U87 GBM cells leads to diminished intratumoral vascular pathologies:
To analyze β8 integrin functions in GBMs in vivo, we forcibly expressed V5-tagged human β8 integrin protein in U87 GBM cells, which express low levels of endogenous β8 integrin ( Figure 1A) . In comparison to control U87 cells transfected with empty vector, increased β8 integrin protein expression was detected in pools of cells stably overexpressing β8-V5 integrin ( Figure 2A) . Next, stably transfected control cells or U87 cells overexpressing β8-V5 protein were injected into the brains of NCR-nu/nu mice (n=5 mice per genotype). After 4 to 6 weeks mice were sacrificed, cardiac-perfused with fixative, and brains were slice coronally to analyze integrin-dependent differences in tumorigenicity. As shown in Figure 2B , U87 cells stably transfected with empty plasmid and U87 cells stably expressing β8-V5 integrin both generated large intracranial tumors. Tumors generated from control U87 cells lacking β8 integrin expression, however, showed grossly obvious hemorrhage and edema. In contrast, U87 tumors expressing β8-V5 protein were vascularized but did not contain severe hemorrhage and edema. Intratumoral blood vessel densities were quantified by immunolabeling U87 tumor sections with anti-CD34 antibodies (n=3 different tumors per cell type, n=3 sections per tumor). As shown in Figure 2C , we detected distended, sinusoidal-like vessels throughout GBMs generated from U87 cells stably transfected with empty plasmids. U87 cells stably overexpressing β8-V5 protein also yielded well-vascularized tumors; however, the abnormal blood vessel morphologies were not evident with most vessels displaying small, capillary-like morphologies. In addition, intratumoral vascular densities, based on quantitation of CD34 fluorescence, were diminished significantly in U87 tumors overexpressing β8 integrin protein ( Figure 2D ).
RNAi-mediated silencing of β8 integrin gene expression impacts angiogenesis and tumor
cell invasiveness in human GBMs: We selected LN229 and SNB19 GBM cell lines that expressed high levels of endogenous β8 integrin protein ( Figure 1A) , and attempted to stably silence integrin expression using lentiviral-delivered shRNAs. These efforts resulted in only ~60% reduction in β8 integrin protein expression in pools of stably transfected cells (data not shown). Analysis of in vitro and in vivo growth and invasive properties in LN229 and SNB19 cells expressing diminished β8 integrin protein, however, did not reveal obvious differences in comparison to control cells (data not shown). Our prior studies of cultured astrocytes and neural progenitors from β8+/-mice, which express 50% less β8 integrin protein in comparison to wild type controls, revealed no differences in cell behaviors (data not shown), suggesting that nearly complete silencing of integrin expression is likely required to reveal functional roles in cells.
Therefore, we stably silenced β8 integrin expression in transformed human astrocytes (THAs), which express lower levels of β8 integrin protein ( Figure 1A ) and represent a more genetically formed from THAs expressing diminished β8 integrin protein were significantly larger, and showed severe edema and hemorrhage ( Figure 3C ). Quantitation of tumor volumes in H&E stained histological sections revealed that astrocytomas expressing β8 shRNAs were significantly larger ( Figure 3D, left panel) . Kaplan-Meier survival comparisons revealed that mice harboring astrocytomas expressing β8 shRNAs died significantly earlier ( Figure 3D , right panel), likely due to larger tumor sizes and associated neurological deficits.
Coronal sections were H&E-stained to reveal that THAs expressing control shRNAs were well vascularized, with intratumoral endothelial cells expressing laminin ( Figure 4A , left panels). Astrocytomas expressing β8 shRNAs contained obvious abnormalities in blood vessel morphologies as revealed by H&E and anti-laminin staining ( Figure 4A , right panels), with many vessel displaying distended, sinusoidal-like morphologies. Quantitation of intratumoral blood vessels by anti-CD34 immunofluorescence and quantitation using ImageJ software revealed significantly higher numbers of vessels in astrocytomas expressing β8 shRNAs ( Figure 4B ).
Astrocytomas expressing scrambled shRNAs grew in periventricular regions of the brain and were infiltrative, with invading astrocytoma cells detected several microns from the main tumor mass ( Figure 4C , left panels). In contrast, THAs expressing β8 shRNAs generated larger, noninfiltrative astrocytomas. Dissemination of GFP-expressing tumors cells into the surrounding brain parenchyma was not detected in the absence of β8 integrin expression ( Figure 4C , right panels). Invasion assays through three-dimensional ECM were also used to quantify integrindependent THA invasion. As shown in Figure 4D , in comparison to THAs expressing scrambled shRNAs, cells expressing β8 shRNAs showed a significant decrease in invasiveness. This integrin-dependent defect in cell invasion was not specific for THAs, since LN229 human GBM cells, which express robust levels of β8 integrin ( Figure 1A) , showed a significant reduction in invasiveness following transient siRNA-mediated silencing of β8 integrin expression (Supplemental Figure 5) . Hypoxia within the tumor microenvironment has been reported to influence GBM cell growth and invasiveness; for example, mouse astrocytoma cells genetically null for hypoxia inducible factor 1 α (Hif1α) or the Hif1α-inducible gene, VEGF-A, show highly invasive intracranial growth patterns (35) . To address potential functional links between hypoxia and αvβ8 integrin-mediated astrocytoma cell invasiveness, Hif1α protein levels were interrogated in astrocytomas derived from control THAs or THAs manipulated to express diminished levels of β8 integrin (n=3 tumors per cell type, n=3 sections per tumor). In comparison to tumors expressing control shRNAs (Supplemental Figure 6A) , we detected elevated levels of Hif1α protein in tumors expressing β8 shRNAs (Supplemental Figure 6B) . Integrin-dependent increases in Hif1α protein expression were not detected in vitro (Supplemental Figure 6C) . We detected an approximately 50% reduction in VEGF-A protein in THAs expressing β8 shRNAs (Supplemental Figure 6D) , although integrin-dependent differences in VEGF-A protein expression in astrocytoma sections were not evident (data not shown). Taken together, these data suggest that β8 integrin is interconnected with the Hif1α/VEGF-A signaling cascade, and these events drive astrocytoma cell invasiveness.
β8 integrin-mediated TGFβ activation and signaling are essential for astrocytoma cell polarity and directional migration:
In the developing brain β8 integrin is a receptor for ECM-bound latent TGFβs, and mediates their activation and subsequent receptor engagement (36) . To investigate roles for αvβ8 integrin-mediated TGFβ activation in astrocytoma cells, THAs expressing scrambled shRNAs or β8 shRNAs were transiently transfected with a reporter plasmid consisting of the TGFβ-responsive PAI1 promoter driving expression of firefly luciferase (27) . Levels of firefly luciferase activity were analyzed after 24 hours. As shown in Figure 5A , approximately four-fold less luciferase activities were detected in THAs expressing β8 shRNAs, reflecting diminished integrin is a mediator of latent TGFβ1 activation and signaling in astrocytoma cells are consistent with our prior data revealing that neural stem and progenitor cells also utilize β8 integrin to activate latent TGFβs to control cell growth and differentiation in neurogenic regions of the mouse brain (19) .
Astrocytoma cell polarity and directional migration were next analyzed using in vitro scratch-wound assays (37) . Confluent monolayers of THAs expressing scrambled shRNAs or β8 shRNAs (n=3 different samples per cell type) were wounded using a pipet tip. After two hours polarity was monitored by labeling cells with phalloidin or anti-paxillin antibodies to visualize the actin cytoskeletal network and cell-ECM contacts, respectively. THAs expressing control shRNAs displayed paxillin-positive adhesion sites at the leading edge (Supplemental Figure 7A ), whereas THAs expressing β8 shRNAs displayed fewer paxillin-containing focal adhesion complexes at their leading edges (Supplemental Figure 7B) . THAs expressing scrambled shRNAs polarized in the direction of the wound and formed well-organized actin cytoskeletal networks (Supplemental Figure 7C) ; in contrast, THAs expressing β8 shRNAs showed diminished polarization at the wound edge, with few cells forming actin-rich projections into the wound region (Supplemental Figure 7D) . Over a 24-hour period THAs expressing scrambled shRNAs largely filled the wound region, whereas migration by THAs expressing β8 shRNAs was significantly impaired as evidenced by failure to fill the wound area at 24 hours ( Figure 5B ).
TGFβs have been reported to promote cell migration in development and cancer (38, 39) ; therefore, we analyzed whether active TGFβs might enhance THA migration in vitro. As shown in Figure 5B , addition of 1 ng/ml of TGFβ1 enhanced directional migration in THAs expressing β8 shRNAs. To quantify roles for integrin-mediated TGFβ activation in THA migration, we imaged cell motility over 48 hours using time-lapse bright field microscopy (Supplemental Figure 7) . THAs expressing scrambled shRNAs required approximately 24 hours to fill the wound regions, whereas THAs expressing β8 shRNAs required nearly 36 hours to fill the wound ( Figure 5C ). Exogenous addition of TGFβ1 showed a statistically significant rescue of the migration defects in THAs expressing β8 shRNAs ( Figure 5C and Supplemental Figure 7 ). These data reveal that the β8 integrin-dependent astrocytoma cell polarity and migration defects are due, in part, to defective integrin-activated TGFβ signaling. These results also support our in vivo data showing diminished invasion by astrocytoma cells lacking β8 integrin (Figure 4) , and support a model in which β8 integrin-mediated TGFβ activation is differentially involved in GBM neovascularization and tumor cell invasiveness ( Figure 6 ). 
Discussion:
The data in this report reveal for the first time that αvβ8 integrin, via activation of its latent TGFβ protein ligands, plays central roles in regulating GBM-induced angiogenesis and perivascular tumor cell invasiveness. While various reports have shown elevated levels of TGFβ receptor signaling (40) (41) (42) in GBM cells, the factors that activate latent TGFβs within the tumor microenvironment remain obscure. Our data demonstrate that αvβ8 integrin is a positive regulator of the TGFβ signaling cascade in invasive GBM cells. We propose that distinct populations of GBM cells selectively express high versus low levels of αvβ8 integrin, with integrin protein expression levels directly determining tumor cell behaviors ( Figure 6 ). While the exact mechanisms that regulate β8 integrin expression in GBM cells remain obscure, a recent report has shown that β8 integrin is a direct target for miR-93, with mIR-mediated inhibition of β8 integrin expression correlating with enhanced angiogenesis and tumorigenicity (43) . Therefore, it is enticing to speculate that during tumor growth and progression sub-populations of GBM cells selectively express high levels of miR-93, thus leading to diminished levels of β8 integrin and the development of angiogenesis pathologies. In contrast, we postulate that invasive GBM cells express low levels of mIR-93 and high levels of β8 integrin, leading to pro-invasive behaviors likely via autocrine activation of TGFβ signaling pathways. Interestingly, p38 and Sp-1 have also been reported to regulate β8 integrin gene expression (44) , suggesting that genetic and epigenetic events may cooperatively control β8 integrin expression and functions in GBMinduced angiogenesis and tumor cell invasiveness.
Putative tumor suppressor-like roles for αvβ8 integrin have been reported in malignant cancers of the lung (45) and skin (46) . Although adult β8-/-mice do not develop spontaneous brain tumors (19), we have found that THAs expressing diminished levels of β8 integrin form more colonies in vitro in soft agar assays and generate significantly larger astrocytomas in vivo, suggesting growth suppressive functions for this integrin. Tumor suppressor-like roles for 
integrin αvβ3 have been reported in mouse models of GBM. For example, in mouse astrocytoma cells αvβ3 integrin normally suppresses cell proliferation and genetic ablation of β3 integrin expression leads to enhanced tumorigenicity (47) . However, human GBMs often display elevated levels of αvβ3 integrin, suggesting roles for this integrin in promoting tumor cell growth and/or invasion (48, 49) . Indeed, small molecule inhibitors of αvβ3 cause diminished GBM cell growth and invasiveness in vitro and in vivo (50) . αvβ3 integrin has been reported to activate focal adhesion kinase in cultured GBM cells (51) and inhibition of focal adhesion kinase activities leads to diminished GBM cell growth in vivo (52) . It will be interesting to determine if reveals that mice harboring tumors generated from THAs expressing β8 shRNAs die earlier than animals harboring tumors generated from THAs expressing control shRNAs (right graph), *p<0.05. The mean survival times for mice bearing tumors derived from control THAs is 84 days, whereas the mean survival for mice harboring tumors derived from THAs expressing β8 shRNAs is 62 days. 
